This page contains brief information about pemigatinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pemigatinib is approved to treat adults with:
- Cholangiocarcinoma (bile duct cancer) that has spread or cannot be removed by surgery. It is used in patients whose cancer has already been treated and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene.¹
- Myeloid or lymphoid cancer that has come back or did not respond to treatment and has a certain change in the structure of the FGFR1 gene.
¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that pemigatinib provides a clinical benefit in these patients.
Pemigatinib is also being studied in the treatment of other types of cancer.
More About Pemigatinib
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
MedlinePlus Information on Pemigatinib - A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Pemigatinib - Check for trials from NCI's list of cancer clinical trials now accepting patients.